Fu Yu Reverses Losses With $72k Net Profit in H1 2024
Fu Yu Reverses Losses With $72k Net Profit in H1 2024
Revenue from its supply chain management arm, Fu Yu Supply Chain Solutions (FYSCS) more than tripled to $72.0m from $18.6m due to higher demand amidst a global economic recovery.Revenue grew 78% to $126.7m.
營業收入增長了78%至12670萬美元。
Fu Yu reported a net profit of $72,000 for H1 2024, rebounding from the $3.9m loss incurred a year ago.
富裕集團報告2024年上半年淨利潤爲72,000美元，從一年前的390萬美元虧損中反彈。
Revenue for the period grew 78.0% to $126.7m, boosted by stronger contributions from both the manufacturing and supply chain management segments.
該期營業收入增長78.0%，至12670萬美元，由於製造業和供應鏈管理部門的貢獻增強。
Revenue from its supply chain management arm, Fu Yu Supply Chain Solutions (FYSCS) more than tripled to $72.0m from $18.6m due to higher demand amidst a global economic recovery.
由於全球經濟復甦帶來的需求增加，富裕供應鏈解決方案（FYSCS）的營業收入猛增至7200萬美元，是1860萬美元的三倍多。
Meanwhile, gross profit from the manufacturing segment rose 12.9% to $7.0m from $6.2m a year ago.
與一年前的620萬美元相比，製造業部門的毛利潤從700萬美元上升了12.9%。
In a bourse filing, the company said that its manufacturing business grew 4% to $54.8m in H1 2024, driven by higher sales from Singapore and Malaysia, partially offset by lower turnover in China.
在交易所提交的文件中，該公司表示，其製造業務在2024年上半年增長了4%，達到5480萬美元，受新加坡和馬來西亞銷售增加驅動，部分抵消了中國業務的萎縮。
Revenue from Singapore and Malaysia rose 6.6% to $21.0m and 39.1% to $17.8m, respectively, whilst revenue from China fell 20.4% to $16.0m. In addition, the higher-margin biomedical segment contributed 3.0% to total revenue for H1 2024.
新加坡和馬來西亞的營業收入分別增長了6.6%和39.1%，分別達到2100萬美元和1780萬美元，而來自中國的營業收入下降了20.4%，只有1600萬美元。此外，高利潤的生物醫藥部門爲2024年上半年總營收做出了3.0%的貢獻。
